Article
Clinical Neurology
Adriana Pero, Anna Pace, Mandip S. Dhamoon
Summary: This study aimed to investigate the prevalence of triptan use among patients with migraine who have contraindications to triptan usage and the specifics of the medication prescribed. The results showed that a considerable proportion of patients with contraindications were still prescribed triptan medication.
Article
Clinical Neurology
Richard B. Lipton, Andrew Blumenfeld, Christopher M. Jensen, Robert Croop, Alexandra Thiry, Gilbert L'Italien, Beth A. Morris, Vladimir Coric, Peter J. Goadsby
Summary: This post-hoc analysis examined the efficacy of riemegpant in treating migraine in adults based on triptan treatment experience. The results showed that riemegpant was effective in all groups, except for triptan-naive participants.
Article
Clinical Neurology
Jae Hyun Lee, Anand R. Shewale, Douglas Barthold, Beth Devine
Summary: This study evaluated the geographic variations in triptan and opioid prescribing patterns for patients with migraine. Results showed that opioids were widely used, while triptans were less commonly prescribed. The findings suggest that there is room for improvement in the acute treatment of migraine attacks.
Review
Medicine, General & Internal
Jun Hua Lim, Leila Karimi, Tissa Wijeratne
Summary: The study revealed that treatment practices for acute migraine in the emergency department are heterogeneous and deviate from established international recommendations, with concerning trends towards underutilization of triptans and overutilization of opioids in many institutions.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Clinical Neurology
Simona Sacco, Christian Lampl, Faisal Mohammad Amin, Mark Braschinsky, Christina Deligianni, Derya Uluduz, Jan Versijpt, Anne Ducros, Raquel Gil-Gouveia, Zaza Katsarava, Paolo Martelletti, Raffaele Ornello, Bianca Raffaelli, Deirdre M. Boucherie, Patricia Pozo-Rosich, Margarita Sanchez-del-Rio, Alexandra Sinclair, Antoinette Maassen van den Brink, Uwe Reuter
Summary: This study aims to provide a definition of triptan failure, which can quantitatively assess the efficacy of triptans in clinical practice and help explore new acute migraine treatments.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Public, Environmental & Occupational Health
Marja-Liisa Sumelahti, Merika S. Sumanen, Kari J. Mattila, Lauri Sillanmaki, Markku Sumanen
Summary: The study found that the risk for comorbid cardio- and cerebrovascular diseases is higher in the working-aged migraine population of Finland, especially among women. Self-reported hypertension, high serum cholesterol, and any diabetes were more common among migraineurs compared to controls.
Article
Clinical Neurology
Olafur B. Davidsson, Isa A. Olofsson, Lisette J. A. Kogelman, Michael Asger Andersen, Klaus Rostgaard, Henrik Hjalgrim, Jes Olesen, Thomas Folkmann Hansen
Summary: Over a 25-year period, triptan use in Denmark has increased, but patient adherence remains low, likely due to disappointing efficacy and/or unpleasant side effects. Triptan discontinuation rates are high, indicating poor implementation of clinical guidelines.
Article
Multidisciplinary Sciences
Lisette J. A. Kogelman, Katrine Falkenberg, Filip Ottosson, Madeleine Ernst, Francesco Russo, Valdemar Stentoft-Hansen, Samuel Demharter, Peer Tfelt-Hansen, Arieh S. Cohen, Jes Olesen, Thomas Folkmann Hansen
Summary: This study aimed to uncover the mechanisms of triptan using metabolomics and transcriptomics in spontaneous migraine attacks. It found three differential metabolites associated with triptan treatment: cortisol, sumatriptan, and glutamine. The change in sumatriptan levels correlated with a change in the expression of GNAI1 and VIPR2 genes, which are known to regulate cAMP levels. Additionally, the study revealed the effect of triptans on fatty acid oxidation, a mechanism previously not associated with triptans but known to be involved in migraine.
SCIENTIFIC REPORTS
(2023)
Article
Clinical Neurology
Karin Zebenholzer, Walter Gall, Andreas Gleiss, Antun R. Pavelic, Christian Woeber
Summary: This study investigated the vascular comorbidity in users and nonusers of triptans over the age of 50. The results showed that there was no significant difference in vascular comorbidity between the two groups, suggesting that triptan use does not increase vascular risk in patients with migraine over the age of 50. However, regular evaluation for contraindications and vascular risk factors is still recommended in this age group.
Article
Chemistry, Physical
Liping Fang, Shan He, Peng Yin, Ning Wang, Bin Zhang, Haixiao Jin
Summary: This study presents the design, synthesis, and evaluation of a series of novel tryptamine derivatives with 5-HT 1B R activation. Several compounds were identified as more potent 5-HT 1B R activators compared to the FDA-approved drug sumatriptan. The molecular docking results provided insights into the binding mode and interactions between the compounds and 5-HT 1B R.
JOURNAL OF MOLECULAR STRUCTURE
(2022)
Article
Clinical Neurology
John H. Krege, Richard B. Lipton, Simin K. Baygani, Mika Komori, Sinead M. Ryan, Maurice Vincent
Summary: The efficacy of lasmiditan in patients with and without triptan contraindications did not differ. Lasmiditan may be a treatment option for patients with contraindications to triptans.
Article
Clinical Neurology
Enrique Martinez-Pias, David Garcia-Azorin, Ane Minguez-Olaondo, Javier Trigo, Alvaro Sierra, Marina Ruiz, Angel L. Guerrero
Summary: The study found that three-quarters of chronic migraine patients did not use triptans, and nonuse of triptans was not solely due to tolerability, frequency of contraindications, or vascular risk factors. Triptan users consumed symptomatic medications fewer days per month, were under prophylactic treatment more frequently, and had medication overuse headache less frequently compared to triptan naive patients.
EXPERT REVIEW OF NEUROTHERAPEUTICS
(2021)
Article
Clinical Neurology
Michele Viana, Grazia Sances, Salvatore Terrazzino, Chiara Zecca, Peter J. Goadsby, Cristina Tassorelli
Summary: The study investigated the association between the efficacy of oral frovatriptan and clinical characteristics of migraine attacks, finding that unilateral pain, phonophobia, cranial autonomic symptoms, and premonitory symptoms were associated with treatment response.
Article
Clinical Neurology
Giulia Hyeraci, Olga Paoletti, Luigi Francesco Iannone, Rosa Gini, Francesco De Cesaris, Pierangelo Geppetti, Giuseppe Roberto
Summary: This study aimed to describe the utilization pattern of anti-CGRP mAbs and the variation in triptan consumption after treatment initiation in the Tuscany region, Italy. The study found a low persistence rate but a high switch rate for anti-CGRP mAbs. Triptan consumption showed a slight decrease compared to baseline during the 15-month follow-up period.
Article
Medicine, Research & Experimental
Linda Harris, Tom O'Connell, Jonathan J. Woolley, Gilbert L'Italien, Tamela Martin, Vladimir Coric, James A. Moren
Summary: The aim of this study is to assess the variations in medication costs among patients using calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for migraine prevention, based on the number of monthly migraine days (MMD). The results showed that medication costs increased significantly with an increase in the number of monthly migraine days.
ADVANCES IN THERAPY
(2023)